Search research articles
Contact Us
Filters
Showing results (51-60 of 85) with videos related to
Page
of 9
Sort By:
BMC Cancer
|
April 18, 2015
Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients
Mirco Pistelli, Mariagrazia De Lisa, Zelmira Ballatore, et al.
Current Drug Targets
|
October 19, 2019
Combining Radiotherapy with Immunocheckpoint Inhibitors or CAR-T in Renal Cell Carcinoma
Matteo Santoni, Daniel Y C Heng, Gaetano Aurilio, et al.
Tumori
|
October 10, 2014
Safety and efficacy of bevacizumab in combination with first-line chemotherapy in advanced breast cancer: data from the Italian cohort of the ATHENA trial
Giuseppina Sanna, Alessandra Fabi, Diana Crivellari, et al.
European Urology Focus
|
February 23, 2022
Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors
Matteo Santoni, Francesco Massari, Sergio Bracarda, et al.
Clinical Genitourinary Cancer
|
March 20, 2022
Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison
Matteo Santoni, Gaetano Aurilio, Francesco Massari, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 3, 2022
Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma
Matteo Santoni, Francesco Massari, Marc R Matrana, et al.
Breast Cancer Research and Treatment
|
April 6, 2012
Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study
Marta Pestrin, Silvia Bessi, Fabio Puglisi, et al.
Expert Review of Cardiovascular Therapy
|
December 13, 2019
Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies
Matteo Santoni, Alessandro Conti, Francesco Massari, et al.
Biochemistry and Biophysics Reports
|
August 18, 2025
mRNA expression, tumor heterogeneity, and response to therapy in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1α)
Cristina Aguzzi, Simona De Summa, Javier Molina-Cerrillo, et al.
Therapeutic Advances in Medical Oncology
|
March 3, 2022
Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib
Sara Elena Rebuzzi, Luigi Cerbone, Alessio Signori, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 85) with videos related to
Sort By:
Page
of 9
BMC Cancer
|
April 18, 2015
Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients
Mirco Pistelli, Mariagrazia De Lisa, Zelmira Ballatore, et al.
Current Drug Targets
|
October 19, 2019
Combining Radiotherapy with Immunocheckpoint Inhibitors or CAR-T in Renal Cell Carcinoma
Matteo Santoni, Daniel Y C Heng, Gaetano Aurilio, et al.
Tumori
|
October 10, 2014
Safety and efficacy of bevacizumab in combination with first-line chemotherapy in advanced breast cancer: data from the Italian cohort of the ATHENA trial
Giuseppina Sanna, Alessandra Fabi, Diana Crivellari, et al.
European Urology Focus
|
February 23, 2022
Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors
Matteo Santoni, Francesco Massari, Sergio Bracarda, et al.
Clinical Genitourinary Cancer
|
March 20, 2022
Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison
Matteo Santoni, Gaetano Aurilio, Francesco Massari, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 3, 2022
Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma
Matteo Santoni, Francesco Massari, Marc R Matrana, et al.
Breast Cancer Research and Treatment
|
April 6, 2012
Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study
Marta Pestrin, Silvia Bessi, Fabio Puglisi, et al.
Expert Review of Cardiovascular Therapy
|
December 13, 2019
Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies
Matteo Santoni, Alessandro Conti, Francesco Massari, et al.
Biochemistry and Biophysics Reports
|
August 18, 2025
mRNA expression, tumor heterogeneity, and response to therapy in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1α)
Cristina Aguzzi, Simona De Summa, Javier Molina-Cerrillo, et al.
Therapeutic Advances in Medical Oncology
|
March 3, 2022
Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib
Sara Elena Rebuzzi, Luigi Cerbone, Alessio Signori, et al.
Page
of 9